David Margel
Overview
Explore the profile of David Margel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
1090
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gerald T, Woldu S, Halstuch D, Ber Y, Lifshitz K, Cook G, et al.
Urol Oncol
. 2025 Feb;
PMID: 39956691
Introduction: While BCG remains standard of care adjuvant treatment for high-risk nonmuscle invasive bladder cancer (NMIBC), predicting response to BCG therapy is difficult. PD-L1 expression in the tumor microenvironment is...
2.
Duivenvoorden W, Margel D, Subramony Gayathri V, Duceppe E, Yousef S, Naeim M, et al.
JACC Basic Transl Sci
. 2024 Apr;
9(3):364-379.
PMID: 38559622
Low testosterone (T), common in aging men, associates with cardiovascular disease. We investigated whether follicle-stimulating hormone (FSH), which is affected by T, modulates the cardiovascular effects associated with low T...
3.
Herzberg H, Babaoof R, Marom R, Veredgorn Y, Savin Z, Lifshitz K, et al.
Eur Urol Focus
. 2024 Mar;
10(5):796-804.
PMID: 38508896
Background And Objective: We compared the oncologic outcomes of patients with non-muscle invasive bladder cancer (NMIBC) who underwent transurethral resection of bladder tumor (TUBRT) using sterile water vs glycine irrigation....
4.
Nelson A, Lopes R, Hong H, Hua K, Slovin S, Tan S, et al.
JACC CardioOncol
. 2023 Nov;
5(5):613-624.
PMID: 37969642
Background: Androgen deprivation therapy is the cornerstone of treatment for patients with advanced prostate cancer. Meta-analysis of small, oncology-focused trials suggest gonadotropin-releasing hormone (GnRH) antagonists may be associated with fewer...
5.
Tamir S, Dahan Shemesh M, Margel D, Bar Y, Yakimov M, Rapson Y, et al.
Isr Med Assoc J
. 2023 Sep;
25(9):601-607.
PMID: 37698310
Background: Age-related changes in multiparametric magnetic resonance imaging (mpMRI) of the prostate have been reported in the general population but not in screening cohorts. Objectives: To evaluate age-related changes on...
6.
Keizman D, Frenkel M, Peer A, Rosenbaum E, Sarid D, Leibovitch I, et al.
Nutrients
. 2023 Aug;
15(16).
PMID: 37630724
The optimal therapy for patients with non-metastatic biochemically relapsed prostate cancer (BRPC-M0) after local therapy is elusive. Thus, the evaluation of new non-toxic compounds in BRPC-M0 patients is warranted. PectaSol-Modified...
7.
Golan S, Frumer M, Zohar Y, Rosenbaum E, Yakimov M, Kedar D, et al.
Eur Urol Oncol
. 2022 Oct;
6(2):151-159.
PMID: 36216740
Background: High-risk localized prostate cancer (HRLPC) has a substantial risk of disease progression despite local treatment. Neoadjuvant systemic therapy before definitive local therapy may improve oncological outcomes by targeting the...
8.
9.
Keizman D, Frenkel M, Peer A, Kushnir I, Rosenbaum E, Sarid D, et al.
Nutrients
. 2021 Dec;
13(12).
PMID: 34959847
Optimal therapy of biochemically relapsed prostate cancer (BRPC) after local treatment is elusive. An established modified citrus pectin (PectaSol, P-MCP), a dietary polysaccharide, is an established antagonist of galectin-3, a...
10.
Margel D, Bernstine H, Groshar D, Ber Y, Nezrit O, Segal N, et al.
Radiology
. 2021 Aug;
301(2):379-386.
PMID: 34463555
Background Gallium 68 (Ga) prostate-specific membrane antigen (PSMA) PET/MRI may improve detection of clinically significant prostate cancer (CSPC). Purpose To compare the sensitivity and specificity of Ga-PSMA PET/MRI with multiparametric...